Radius Health

+$0.22 (+3.67%) As of 6:37 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Radius Health and other ETFs, options, and stocks.

About RDUS

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis.

CEO

George Kelly Martin

Employees

293

Headquarters

Boston, Massachusetts

Founded

2003

RDUS Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

989.60K

High today

$6.24

Low today

$6.02

Open price

$6.03

Volume

222.37K

52 Week high

$23.00

52 Week low

$4.97

RDUS News

Simply Wall StMay 21

Breakeven On The Horizon For Radius Health, Inc.

With the business potentially at an important milestone, we thought we'd take a closer look at Radius Health, Inc.'s ( ) future prospects. Radius Health, Inc.,

BenzingaMay 20

Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer - Yahoo Finance

The Menarini Group and Radius Health Inc's (NASDAQ: RDUS) data from the phase 3 EMERALD trial evaluating elacestrant for ER+/HER2- advanced or metastatic breast

Analyst ratings

Buy

Hold

71.4%

Sell

28.6%

RDUS Earnings

-$0.42

-$0.23

-$0.04

$0.15

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Estimated

— per share

Actual

Expected Aug 4, Pre-Market

Why Robinhood?

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. View more

Breakeven On The Horizon For Radius Health, Inc.

Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer - Yahoo Finance

71%

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis.